Grant Award Details
- To demonstrate ASR-149, a lead PIKFYVE inhibitor prevents SARS-CoV-2 infection of human alveolar type II cells, and confirm PIKFYVE as the relevant target of ASR-149.
Grant Application Details
- Development of a novel PIKFYVE kinase inhibitor for the treatment of COVID-19
Alveolar type II cells are the stem cells of the lung, and they are killed by SARS-CoV-2. We will determine if a novel PIKFYVE kinase inhibitor prevents SARS-CoV-2 infection of type II cells.
Although PIKFYVE inhibition blocks SARS-CoV-2 infection, no known PIKFYVE inhibitors have suitable drug-like properties. We would validate a novel PIKFYVE inhibitor for the treatment of COVID-19.
Major Proposed Activities
- Confirm ASR-149’s efficacy against SARS-CoV-2 in human iPSC-lung type II cells
- Use antisense oligonucleotides to verify that PIKFYVE inhibition blocks entry of SARS-CoV-2 pseudovirus and live replication competent SARS-CoV-2 virus in human iPSC-lung type II cells
If successful, these studies could lead to an effective treatment for COVID-19 that would reduce suffering from COVID-19 and enable Californians to live without social distancing requirements.